Plant Health Care successfully submits PHC279 for Regulatory Approval in Brazil

Plant Health Care plc (LON:PHC), a leading provider of novel patent-protected biological products to global agriculture markets, has today announced it has successfully submitted its application to the regulatory agencies in Brazil for approval to commercialize the Company’s first peptide product, PHC279, for the control of Asian soybean rust.

Highlights:

–    Plant Health Care’s application for approval to sell novel peptide product PHC279, to treat Asian soybean rust has been submitted to the authorities in Brazil.

–    Review of the application is expected to commence shortly and the Federal regulatory licence is expected in 1-2 years.

As announced on 15 August 2019, the 2018/19 Field trials of PHC279 as a seed treatment in Brazil soybeans, showed up to 45% improved control of Asian soybean rust (ASR) and up to 16% yield increase when compared with foliar fungicide programs alone.  Based on these results, the Company intends to move forward to commercialise PHC279 in Brazil, with regulatory approval expected by the end of this year at the earliest.

Brazil is the world’s largest exporter of soybeans, with some 36 million hectares (89 million acres) planted in 2019.  One of the challenges of producing soybeans in Brazil is ASR, which is a potentially devastating disease.  Growers spent $2.1 billion in 2017 on soybean fungicides in Brazil.

Plant Health Care’s PREtec peptides stimulate the plant to defend itself. Derived from natural proteins, this is a novel, environmentally friendly approach to protecting crops and increasing yields, compatible with mainstream agricultural practice.  PHC279 may allow farmers to reduce applications of toxic fungicides or to achieve better control of disease.

Plant Health Care’s submission for registration of PHC279 for the control of ASR has been accepted by the three responsible Brazilian agencies: the Ministry of Agriculture, Livestock and Food Supply (MAPA), the National Health Surveillance Agency (ANVISA), and the Brazilian Institute of the Environment and Renewable Natural Resources (IBAMA). The Brazilian authorities do not commit to a specific timeline for granting regulatory licences.  However, the Company expects the review to start soon and given PHC279’s environmentally friendly profile and unique mode of action compared with conventional agrochemical products anticipates a regulatory licence will be granted in 1-2 years. 

The Company expects to be in a position to launch the product soon after regulatory licences have been obtained.  Low cost production methods are progressing to scale-up and will be in place before launch. 

Chris Richards, CEO of Plant Health Care said, “PHC279 is the first of many peptides from the Company’s PREtec platform. Submitting our application for regulatory approval in Brazil is the first step towards regulatory approval in Brazil and an important milestone towards commercialising this product. Outside of Brazil, we are preparing to launch this novel technology directly to markets in the U.S. and other countries, initially targeting markets with an opportunity of $5 billion.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Plant Health Care Plc

    More articles like this

    Plant Health Care Plc

    Plant Health Care appoint new Board directors

    Plant Health Care (LON:PHC) has announced three new Board appointments with effect from 1st November 2019. Mr Guy van Zwanenberg FCA will join the PHC Board as a Non-executive Director. He will take over as Chair of the

    Plant Health Care Plc

    Plant Health Care Progress with PREtec field trials in Brazil

    Plant Health Care (LON:PHC), a leading provider of novel patent-protected biological products to global agriculture markets, has today provided the following update in relation to the 2018/19 field trials of the PREtec peptide PHC279 for the

    Plant Health Care Plc

    Plant Health Group plc New Distribution Agreement for Harpin αß

    Plant Health Care plc (LON:PHC), a leading provider of novel patent-protected biological products to global agriculture markets, today announced a new distribution agreement with Wilbur-Ellis Company LLC, a leading U.S. agriculture distributor, for exclusive access to

    Path Investments Plc

    Path Investments plc Update on Heads of Agreement

    Path Investments plc (LON: PATH) today provided an update regarding the Heads of Agreement with ARC Marlborough Pty Limited (“ARC”) in relation to the proposed acquisition of ARC by the Company (the “Proposed Transaction”) announced on

    Plant Health Care Plc

    Plant Health Care Made exciting progress in 2018

    Chris Richards, Plant Health Care Interim CEO, commented: “Plant Health Care continued to make exciting progress in 2018, in spite of recently announced set-backs. The launch of our new corn product in the US holds great

    Plant Health Care Plc

    Plant Health Care Plc ProAct® Wins Top Industry Award

    Chris Richards, Executive Chairman and Interim CEO of Plant Health Care noted: “This award is recognition that Plant Health Care, as a science-based company, can bring new benefits to growers with low toxicity, biological products. We

    Plant Health Care Plc

    Plant Health Care to present at Mello London

    Plant Health Care (LON: PHC), a leading provider of novel patent-protected biological products to global agriculture markets, today announced that the Company will be presenting at the Mello London investor conference on Tuesday 27 November 2018